Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
60.50    0.00 (0.00%)
Bid:
59.00
Ask:
62.00
Spread: 3.00 (5.085%)
Market Cap: £14.74m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Year-end Update

6 Jan 2025 07:00

RNS Number : 1513S
MyCelx Technologies Corporation
06 January 2025
 

06 January 2025

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Year-end Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company founded to transform the environmental impact of industry, is pleased to provide a year-end update on its core markets.

 

2024 has been a year of solid progress interspersed with timeline changes that have been outside our control. In aggregate, the continued progress that we have made in the REGEN and PFAS markets gives us great confidence in both our direction of travel and the future for the Company. Our Saudi Arabia distribution partnership, established subsequent to the sale of our Saudi Arabia operations earlier this year, is growing and diversifying its application base. The Company is pleased to report that it has been informed it will receive over $1million of the first earn out payment that is due in 2025, but will not know the full amount until the reporting period ends in February 2025.

 

Progress in the EOR / REGEN market this year include selling the Saudi Arabia operation mentioned above, the award of a very significant Middle East REGEN contract we announced in October, and three trials, one most recently operating successfully in West Texas that will continue into Q1 2025. As our success in the Middle East continues to build, the incoming Administration in the US has stated it supports US energy independence, which the Company believes will give producers increased confidence to pursue upgrades, beneficial reuse projects and other capital projects to improve water management and performance. MYCELX is well-positioned to take advantage of the opportunities in this changing market with its REGEN media and proprietary Retro-fit systems.

 

Our PFAS business won an AFFF remediation project through a global engineering company and signed a partnership with a preferred Department of Defence contractor that we announced in July. The PFAS team looks forward to wastewater and landfill leachate trials that are expected to commence in January and April of 2025, respectively, that were in different stages of implementation and design in 2024. In Q1 2025, we expect to begin the roll out of mobile PFAS systems through channel partners that will remediate PFAS contamination at small utility sites. The Company believes this is an application that can grow quickly and provide visibility for MYCELX PFAS systems.

 

The Company expects its 2024 year-end revenue to be c.a. $4.9 million, verses market expectations of $4.7 million. PBT and EBITDA is still subject to year-end closing but is expected to be broadly in line with current market expectations and the cash balance of c.a. $1.3 million slightly exceeds expectations. We look forward to continuing to grow our core market businesses in 2025 with momentum and focus, and providing progress updates in due course.

 

For further information, please contact:  

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nominated Adviser and Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSIFFLEISELF
Date   Source Headline
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.